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A 23-year-old woman with a Masaoka stage III type B2/B3 thymoma was referred to our institution for adjuvant 
proton therapy after surgical resection. The patient initially 
presented with chest pain, shortness of breath, and a family 
history notable for her brother having died from metastatic 
thymoma at the age of 17 years. A chest computed tomography 
scan demonstrated a large anterior mediastinal mass. Surgical 
exploration and resection demonstrated a 16.5 × 8.5 × 3.7 cm 
mass invading the innominate vein, requiring graft recon-
struction, and extending along the right paramediastinal/car-
diac border to just above the right hemidiaphragm. Pathology 
revealed stage III type B2/B3 thymoma with no lymph node 
involvement, but microscopic positive margins.
Because of stage and positive margins, recommenda-
tions were made for adjuvant radiation therapy (RT). An RT 
plan was developed to deliver 50.4 Gy to the postoperative 
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FIGURE 1:  Colorwash isodose distribution for intensity-modulated radiation therapy (left) and proton therapy (right). The 
heart is outlined in red, the breasts in yellow, the PTV 50.4 Gy is in dark blue, and the PTV boost is in dark pink. The highest 
radiation therapy doses are represented by red whereas the lowest doses are represented in blue. PTV, planned target volume.
bed with a 10.8 Gy boost to the site that showed microscopic 
residual disease. Despite advanced disease at presentation, 
patients with stage III thymoma receiving adjuvant RT do 
well with a median overall survival of 127 months.1 Because 
this female patient was quite young, it was important to con-
sider the long-term complications of RT to the chest.
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TABLE 1.  Mean Dose to Organs with Intensity-Modulated Radiation Therapy and Proton Therapy
Organ IMRT (Gy) Proton (Gy) Absolute Reduction (Gy) Relative Reduction (%)
Lungs 15.7 9.9 5.8 37
Heart 28.4 20.4 8.0 28
Esophagus 36.5 16.5 20.0 55
Breasts 7.6 9.7 2.1 −27
Nontarget thoraxa 8.7 3.6 5.1 59
aNontarget thorax refers to thorax minus planned target volume. 
Unfortunately, even with the most conformal pho-
ton radiation technique, intensity-modulated radiotherapy 
(IMRT), the mean dose to the organs at risk was quite high. 
The patient was, therefore, referred to University of Florida 
Proton Therapy Institute for consideration of treatment with 
proton therapy.
Conventional photon RT, which uses high-energy pho-
tons, deposits part of the RT dose throughout the beam’s 
path, causing collateral damage to normal tissue ahead of and 
behind the actual planned target volume (PTV). Conversely, 
proton therapy, which uses charged particles, deposits most of 
the RT dose at the PTV, with a lower entrance dose (ahead of 
the PTV) and little to no exit dose (behind the PTV) compared 
with high-energy photons.
Our patient underwent treatment planning with IMRT 
and proton therapy. Figure 1 shows the colorwash isodose 
plans comparing the dose distributions of both plans. Figure 
2 shows dose-volume histograms of the OARs. Table 1 shows 
mean doses to the OARs.
RT doses as low as 4 to 5 Gy to the lung and/or breast 
have been associated with an increased risk of secondary 
lung and breast cancers,2,3 whereas RT doses as low as 5 to 
15 Gy to the heart have been shown to increase the risk of 
late cardiac injury, such as myocardial infarction, conges-
tive heart failure, and valvular disease.4,5 Our treatment plans 
showed that, when compared with IMRT, proton therapy 
reduced the mean dose to the heart by 8 Gy, lungs by 6 Gy, 
and esophagus by 20 Gy, whereas it increased the dose to the 
breasts by 2 Gy.
Because of the lower doses delivered to most of the 
OARs and expected lower risk of late toxicity with these lower 
doses, the patient was treated with proton therapy. Proton 
FIGURE 2:  Dose-volume histograms representing the percentage of each organ irradiated at each radiation dose level with 
intensity-modulated radiation therapy (dashed line) or proton therapy (solid line).
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therapy should be considered in similar cases of young adults 
with thymoma, in whom there are concerns of the late toxicity 
associated with RT.
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